MA41480A - Anticorps qui se lient au ccr6 et leurs utilisations - Google Patents

Anticorps qui se lient au ccr6 et leurs utilisations

Info

Publication number: MA41480A
Authority: MA; Morocco
Prior art keywords: ccr6; antibodies bound; antibodies; bound
Prior art date: 2014-10-17

Application number

MA041480A

Other languages

English (en)

Inventor

Stanislas Blein

Samuel Hou

Rami Lissilaa

Jeremy Loyau

Romain Ollier

Adrian Walmsley

Original Assignee

Glenmark Pharmaceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-17

Filing date

2015-10-18

Publication date

2017-12-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41480(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-18 Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa

2017-12-19 Publication of MA41480A publication Critical patent/MA41480A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Zoology (AREA)
Toxicology (AREA)
Dermatology (AREA)
Oncology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Neurology (AREA)

MA041480A 2014-10-17 2015-10-18 Anticorps qui se lient au ccr6 et leurs utilisations MA41480A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP14189374		2014-10-17

Publications (1)

Publication Number	Publication Date
MA41480A true MA41480A (fr)	2017-12-19

Family

ID=51743336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA041480A MA41480A (fr)	2014-10-17	2015-10-18	Anticorps qui se lient au ccr6 et leurs utilisations

Country Status (18)

Country	Link
US (1)	US10640564B2 (fr)
EP (1)	EP3207060A1 (fr)
JP (1)	JP6792552B2 (fr)
KR (1)	KR20170082536A (fr)
CN (1)	CN107108742A (fr)
AU (1)	AU2015332338A1 (fr)
BR (1)	BR112017007877A2 (fr)
CA (1)	CA2964300A1 (fr)
CL (1)	CL2017000912A1 (fr)
CO (1)	CO2017004753A2 (fr)
EA (1)	EA201790816A1 (fr)
IL (1)	IL251676A0 (fr)
MA (1)	MA41480A (fr)
MX (1)	MX2017004970A (fr)
PE (1)	PE20170943A1 (fr)
PH (1)	PH12017500699A1 (fr)
SG (2)	SG11201703002PA (fr)
WO (1)	WO2016059253A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA41480A (fr)	2014-10-17	2017-12-19	Glenmark Pharmaceuticals Sa	Anticorps qui se lient au ccr6 et leurs utilisations
WO2020210816A1 (fr) *	2019-04-12	2020-10-15	Methodist Hospital Research Institute	Particules thérapeutiques permettant à des cellules présentant un antigène d'attaquer des cellules cancéreuses
CN112190708B (zh) *	2019-07-08	2023-09-05	上海交通大学医学院附属瑞金医院	趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
US20230340089A1 (en) *	2020-05-14	2023-10-26	City Of Hope	Smc1a antibodies and uses thereof
JP7214696B2 (ja) *	2020-10-01	2023-01-30	一般財団法人化学物質評価研究機構	新規ｉｎｖｉｔｒｏ皮膚感作性試験法
AU2021398586A1 (en) *	2020-12-14	2023-07-06	Monash University	Ccr6 antibodies
CN118786143A (zh) *	2021-12-29	2024-10-15	南京艾美斐生物医药科技有限公司	抗ccr6抗体及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0307434B2 (fr)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Anticorps alteres
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1993022332A2 (fr)	1992-04-24	1993-11-11	Board Of Regents, The University Of Texas System	Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
MX353234B (es)	1999-01-15	2018-01-08	Genentech Inc	Variantes de polipeptidos con función efectora alterada.
US20040197329A1 (en) *	2000-10-13	2004-10-07	Yasunori Nakayama	Remedies or preventives for rheumatoid arthritis
DE60232265D1 (de)	2001-10-25	2009-06-18	Genentech Inc	Glycoprotein-zusammensetzungen
CN102421800A (zh)	2009-02-23	2012-04-18	格兰马克药品股份有限公司	结合cd19的人源化抗体及其用途
PE20140633A1 (es) *	2010-11-19	2014-05-30	Eisai Randd Man Co Ltd	Anticuerpos neutralizadores anti-ccl20
EA028804B1 (ru) *	2011-03-25	2018-01-31	Гленмарк Фармасьютикалс С.А.	Гетеродимерные иммуноглобулины
WO2013005649A1 (fr)	2011-07-01	2013-01-10	協和発酵キリン株式会社	Anticorps anti-ccr6 humain
JP2014521089A (ja) *	2011-07-13	2014-08-25	メルク・シャープ・アンド・ドーム・コーポレーション	液体試料中のアミロイドベータオリゴマーの検出方法およびその使用
WO2013184218A1 (fr) *	2012-06-05	2013-12-12	Msm Protein Technologies	Anticorps monoclonaux humains dirigés contre le récepteur ccr6 de chémokine humain
MA41480A (fr)	2014-10-17	2017-12-19	Glenmark Pharmaceuticals Sa	Anticorps qui se lient au ccr6 et leurs utilisations

2015
- 2015-10-18 MA MA041480A patent/MA41480A/fr unknown
- 2015-10-19 EP EP15781677.8A patent/EP3207060A1/fr not_active Withdrawn
- 2015-10-19 AU AU2015332338A patent/AU2015332338A1/en not_active Abandoned
- 2015-10-19 EA EA201790816A patent/EA201790816A1/ru unknown
- 2015-10-19 BR BR112017007877A patent/BR112017007877A2/pt not_active Application Discontinuation
- 2015-10-19 CN CN201580069220.2A patent/CN107108742A/zh active Pending
- 2015-10-19 PE PE2017000723A patent/PE20170943A1/es unknown
- 2015-10-19 MX MX2017004970A patent/MX2017004970A/es unknown
- 2015-10-19 SG SG11201703002PA patent/SG11201703002PA/en unknown
- 2015-10-19 KR KR1020177013237A patent/KR20170082536A/ko not_active Withdrawn
- 2015-10-19 SG SG10201912424UA patent/SG10201912424UA/en unknown
- 2015-10-19 US US15/519,413 patent/US10640564B2/en not_active Expired - Fee Related
- 2015-10-19 JP JP2017520318A patent/JP6792552B2/ja not_active Expired - Fee Related
- 2015-10-19 CA CA2964300A patent/CA2964300A1/fr not_active Abandoned
- 2015-10-19 WO PCT/EP2015/074178 patent/WO2016059253A1/fr active Application Filing
2017
- 2017-04-09 IL IL251676A patent/IL251676A0/en unknown
- 2017-04-12 CL CL2017000912A patent/CL2017000912A1/es unknown
- 2017-04-12 PH PH12017500699A patent/PH12017500699A1/en unknown
- 2017-05-11 CO CONC2017/0004753A patent/CO2017004753A2/es unknown

Also Published As

Publication number	Publication date
AU2015332338A1 (en)	2017-06-01
US20180086836A1 (en)	2018-03-29
CA2964300A1 (fr)	2016-04-21
EA201790816A1 (ru)	2018-03-30
SG10201912424UA (en)	2020-02-27
BR112017007877A2 (pt)	2018-01-23
KR20170082536A (ko)	2017-07-14
PE20170943A1 (es)	2017-07-13
CO2017004753A2 (es)	2017-09-29
MX2017004970A (es)	2017-06-30
JP2017536101A (ja)	2017-12-07
US10640564B2 (en)	2020-05-05
SG11201703002PA (en)	2017-05-30
CN107108742A (zh)	2017-08-29
IL251676A0 (en)	2017-06-29
PH12017500699A1 (en)	2017-10-09
CL2017000912A1 (es)	2017-12-15
WO2016059253A1 (fr)	2016-04-21
JP6792552B2 (ja)	2020-11-25
EP3207060A1 (fr)	2017-08-23

Publication	Publication Date	Title
FR24C1023I1 (fr)	2024-07-26	Anticorps thérapeutiques et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
EP3383916A4 (fr)	2019-09-11	Anticorps anti-cd73 et leurs utilisations
EP3426288A4 (fr)	2019-10-30	Anticorps anti-pacap et leurs utilisations
MA45235A (fr)	2019-04-17	Anticorps anti-c5 et leurs utilisations
MA49687A (fr)	2020-06-03	Anticorps anti-ctla-4 et leurs utilisations
MA53184A (fr)	2021-05-26	Anticorps anti-ox40 et leurs utilisations
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr)	2019-08-14	Anticorps anti-lag-3 et leurs utilisations
MA46708A (fr)	2021-05-05	Anticorps anti-pd1 et leurs utilisations
EP3328895A4 (fr)	2019-08-21	Anticorps anti-pd-l1 et leurs utilisations
MA49683A (fr)	2020-06-03	Anticorps anti-cd8 et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
MA43186A (fr)	2021-04-07	Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MA44723A (fr)	2019-02-27	Anticorps agonistes se liant au cd40 humain et leurs utilisations
EP3283516A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
MA42935A (fr)	2018-08-01	Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
EP3377102A4 (fr)	2019-07-10	Anticorps anti-pd-1 et leurs utilisations thérapeutiques
MA53400A (fr)	2021-08-04	Hétéromultimères alk7: actriib et leurs utilisations
MA49565A (fr)	2020-05-20	Anticorps agonistes qui lient cd137 humain et leurs utilisations
EP3534937C0 (fr)	2023-09-27	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
EP2970505A4 (fr)	2016-10-19	Anticorps bispécifiques et leurs utilisations
EP2961774A4 (fr)	2016-10-26	Anticorps d'alpha-synucléine et leurs utilisations
MA45233A (fr)	2019-04-17	Anticorps anti-gitr et leurs utilisations